{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
deferoxamine
to a specific field?
Status:
US Approved Rx
(2012)
Source:
BLA125409
(2012)
Source URL:
First approved in 2012
Source:
BLA125409
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:anbenitamab repodatecan [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pertuzumab zuvotolimod [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:zirconium (89Zr) girentuximab senvedoxam [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04692831: Phase 1 Interventional Active, not recruiting HER-2 Positive Malignant Carcinoma of Breast
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01832051: Phase 2 Interventional Completed Metastatic Breast Cancer
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:zirconium (⁸⁹Zr) crefmirlimab berdoxam [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03733210: Phase 1 Interventional Completed Squamous Cell Carcinoma of the Head and Neck
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02760225: Not Applicable Interventional Completed Melanoma
(2016)
Source URL:
Class:
PROTEIN
